155526-40-2

Upstream product

• 57-57-8 β-Propiolactone 
• 60-12-8 2-phenylethanol 
• 154189-76-1 3-(2-phenylethoxy)-1-propanol 
• 5468-00-8 Phenylacetaldehyde trimethylene acetal 
• 133803-49-3 tert-butyl 3-(2-phenylethoxy)propanoate 

Downstream Products

• 948895-95-2 8-(benzyloxy)-5-{(1R)-1-{[tert-butyl(dimethyl)silyl]oxy}-2-[({(2S)-1-[3-(2-phenylethoxy)propyl]pyrrolidin-2-yl}methyl)amino]ethyl}quinolin-2(1H)-one 
• 948895-97-4 8-(benzyloxy)-5-{(1R)-1-hydroxy-2-[({(2S)-1-[3-(2-phenylethoxy)propyl]pyrrolidin-2-yl}methyl)amino]ethyl}quinolin-2(lh)-one 
• 948895-93-0 1-{(2S)-1-[3-(2-phenylethoxy)propyl]pyrrolidin-2-yl}methanamine 
• 1314899-82-5 C₂₆H₃₅N₃O₄S 
• 928663-70-1 N-butyl-N-(2-oxo-ethyl)-3-phenethyloxy-propionamide 
• 1035229-13-0 N-cyclohexyl-N-(2,2-dimethoxyethyl)-3-phenethoxypropanamide 
• 948895-91-8 1-[3-(2-phenylethoxy)propanoyl]-L-prolinamide 
• 215036-15-0 2-Methyl-2-(3-phenethyloxy-propionylamino)-propionic acid 
• 215036-11-6 4,4-Dimethyl-2-(2-phenethyloxy-ethyl)-4H-oxazol-5-one 
• 1035229-55-0 3-phenethoxypropanoyl chloride 

Relevant academic research and scientific papers

NOVEL BENZOTHIAZOLONE DERIVATIVES

The present invention provides compounds of formula (I) wherein e, R1, R2, R3, R4, R5, R4, R5, R6, R7, R7a, R7b, A, D, m and n are as

7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS

The present invention provides compounds of formula (I) wherein e, R1, R2, R3, R4, R5, R4', R5', R6, R7, A, D, m and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

The chemistry of 2-alkenyl-5(4H)-oxazolones. VIII acid-catalyzed reaction with alcohols

The acid-catalyzed reaction of 4,4-dimethyl-2-vinyl-5(4H)-oxazolone with primary alcohols proceeded with almost equal frequency at both C=C (Michael addition) and C=O (ring opening) groups; reaction with secondary and tertiary alcohols resulted in a modes

7-(2-AMINOETHYL) BENZOTHIAZOLONES

There are disclosed compounds of formula I, Ar--CH. sub.2 CH 2--NH--CR 1 R 2--X--Y I in whichAr represents a group, STR1 X represents a C. sub.1-12 alkylene chain optionally interrupted or terminated by one or more groups selected from--S(O) n--,--O--,--C(Z)--, CR 6 R. sup.7, phenylmethyne,--NR 8--,--CONH--,--NHCO--and--NHCONH--, Y represents an optionally substituted aryl or cycloalkyl group,Z represents O or S, R 1, R 2, R 5 and R 9 each independently represent hydrogen or alkyl C 1-6,R 3 and R 4 represent hydrogen, or R. sup.3 and R 4 together form a group--S--,--NR 9--or--CH 2--,R 6 and R 7 independently represent hydrogen, alkyl C 1-6, fluoro, cyano, or CF. sub.3, provided that at least one of R 6 and R 7 is other than hydrogen,R 8 represents hydrogen or alkyl C 1-6, or when X is interrupted or terminated by more than one--NR 8--group may together with another R 8 group form the chain--CH 2--CH 2--, andn represents 0, 1 or 2,and pharmaceutically acceptable derivatives thereof.Processes for their production and pharmaceutical compositions and methods of treatment involving their use are also described.